Findings

What do systematic reviews say?

3 questions · 3 findings · 3 reviews · Kidney and Transplant

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 1 · 33.3%High 1 · 33.3%

SGLT2 inhibitors vs placebo

Hypoglycaemia · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 3086 participants
Low

SGLT2 inhibitors vs placebo

Hypoglycaemia · pre‐existing and new‐onset diabetes in kidney transplant recipients

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Moderate

SGLT2 inhibitors vs placebo

Hypoglycaemia requiring third‐party assistance median · people with diabetes and CKD

Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower hypoglycaemia requiring third‐party assistance median compared with placebo (high certainty).

1 finding from 1 review

Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes 2024 · Cochrane Headline outcomes only
RR 0.75 [0.65, 0.88]
14 studies · 26478 participants
High